Drugs Containing Excipient (Inactive Ingredient) POLOXAMER 182

Branded drugs containing POLOXAMER 182 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	DIFFERIN	adapalene	0299-4910	POLOXAMER 182
Alchemee LLC	PROACTIV MD ADAPALENE	adapalene	11410-956	POLOXAMER 182
Physicians Total Care Inc	DIFFERIN	adapalene	54868-5030	POLOXAMER 182
Prasco Laboratories	CLINDAMYCIN - BENZOYL PEROXIDE	clindamycin phosphate and benzoyl peroxide	66993-949	POLOXAMER 182

Generic drugs containing POLOXAMER 182 excipient

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	POLOXAMER 182
Galderma Laboratories LP	adapalene	0299-4910	POLOXAMER 182
CROWN LABORATORIES	adapalene	0316-0143	POLOXAMER 182
CROWN LABORATORIES	adapalene	0316-0284	POLOXAMER 182
Walgreens	adapalene	0363-0888	POLOXAMER 182

Market Dynamics and Financial Trajectory for POLOXAMER 182

Last updated: February 13, 2026

POLOXAMER 182, a nonionic surfactant and solubilizer under the poloxamer class, witnesses limited direct market data due to its specialized use. Its adoption hinges on pharmaceutical formulation needs, particularly in injectables, topical products, and biopharmaceuticals requiring solubilization or stabilization.

What Are the Key Market Drivers?

Growth in Biopharmaceuticals and Injectable Formulations

The rising demand for biologics, including monoclonal antibodies and gene therapies, enhances the need for excipients like POLOXAMER 182. Its surfactant properties improve drug solubility and stability, making it a preferred choice in formulations. The biopharmaceutical segment is projected to record a compound annual growth rate (CAGR) of 7-10% from 2023 to 2028, buoying excipient markets accordingly.

Regulatory Acceptance and Market Penetration

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) list poloxamers as acceptable excipients. Clear regulatory pathways facilitate market entry for drugs using POLOXAMER 182, but specific approval depends on individual formulations.[1]

Market Competition and Product Alternatives

Poloxamer 188 remains the dominant variant with broader documentation and marketing. POLOXAMER 182’s niche positioning means its market share is smaller but potentially expanding due to demand for specialized excipients. Cheaper or more established alternatives like Cremophor or Tween may limit its growth unless regulatory or performance advantages emerge.

Supply Chain and Raw Material Trends

The primary raw material, polypropylene oxide, faces supply constraints linked to global petrochemical markets. Fluctuating raw material prices influence POLOXAMER 182's manufacturing costs, potentially affecting adoption and pricing strategies.

What Is the Financial Trajectory?

Forecasted Revenue Growth

Global excipient market revenues for poloxamers are projected to reach USD 600-800 million by 2028, with a CAGR around 5-7%.[2] POLOXAMER 182's specific share remains small, estimated at approximately 5-10% of total poloxamer sales.

Pricing Trends

Market prices for POLOXAMER 182 vary based on purity, batch size, and supplier. Average prices could range from USD 15-25 per kilogram, with premium formulations commanding higher costs. As demand grows, economies of scale may lower prices slightly, improving margins for suppliers.

Investment and R&D Impact

Manufacturers investing in R&D to improve the performance or expand applications of POLOXAMER 182 could boost future revenues. The pharmaceutical industry’s focus on stability, bioavailability, and scalability guides such investments. Limited existing patents may parlay into market advantages for early developers.

Key Financial Risks

Market size remains limited without broader adoption; over-reliance on biopharmaceutical contracts exposes the asset to sector-specific downturns. Supply chain disruptions and raw material costs further pose risks to profitability.

Summary of Market and Financial Outlook

Factor	Status	Impact
Market Growth	Moderate	Driven by biopharmaceutical demand
Share of Poloxamer Market	5-10%	Small but potentially increasing
Price Range	USD 15-25/kg	Competitive positioning
Investment Trends	R&D focus	Potential for higher margins
Supply Chain	Volatile	Affects pricing and availability

Final Remarks

POLOXAMER 182 operates in a niche space within the excipient market, with growth prospects tied to the expansion of biologics and complex drug formulations. Its financial trajectory depends on regulatory outcomes, raw material costs, and R&D investment success, with potential for modest revenue increases in a stable market.

---

Key Takeaways

• Market expansion for POLOXAMER 182 aligns with growth in biologic and injectable drug formulations.
• Regulatory acceptance is established but product-specific approvals are required.
• Market share remains limited, but early R&D investments could elevate its position.
• Pricing and supply chain factors significantly influence profitability.
• Competitors' established presence constrains rapid adoption without performance advantages.

---

FAQs

1. What clinical applications drive demand for POLOXAMER 182?
It is used primarily in solubilizing and stabilizing formulations of biologics, injectable drugs, and topical applications where solubility enhancement is critical.

2. How does POLOXAMER 182 compare to other poloxamers?
It has a lower molecular weight and different surfactant properties than poloxamer 188, influencing its solubility profile and specific application niches.

3. What regulatory hurdles exist for POLOXAMER 182?
While approved as an excipient, each new formulation using POLOXAMER 182 must undergo specific regulatory reviews for safety and compatibility.

4. How do raw material prices influence POLOXAMER 182?
Prices fluctuate with petrochemical markets affecting polypropylene oxide prices; increased costs elevate manufacturing expenses.

5. What future developments could influence its market share?
Innovations enhancing performance, cost reductions, or expanded regulatory approvals could boost adoption.

---

Citations
[1] U.S. FDA excipient approval list
[2] Market Research Future, "Global Pharmaceutical Excipients Market," 2023